Growth through acquisitions RBS has a track record of strategic acquisitions (Radmax 2020, Apollo Healthcare 2022) and ongoing expansion into oncology services and billing capabilities, signaling potential upsell opportunities around integration projects, revenue cycle optimization, and cross-selling of new care delivery capabilities to existing clients and acquired firms.

ASTRO engagement Recent participation in ASTRO 2025 and launch of Anoma Cancer Collective suggests RBS is actively investing in industry visibility and nonprofit initiatives, creating openings for partnerships, sponsorships, and collaborative programs that can be pitched to current and prospective hospital networks seeking innovation.

Revenue cycle focus Specialization in oncology management and billing underscores opportunities to upsell advanced RCM services, analytics, and consultative optimization for larger oncology footprints, especially with networks nearing federal or payer-driven efficiency targets.

Mid-market footprint With 51-200 employees and $25M-$50M in revenue, RBS sits in a mid-market corridor where scalable billing, management, and software integrations (ERP/practice management, EHR, CRM) can be offered to standardize operations across multi-site oncology practices.

Tech stack leverage Current tech stack includes WordPress, MySQL, SendGrid, and Perl, indicating opportunities to propose modernization projects, API-based integrations, and data automation enhancements to improve patient communications, credentialing, and claims processing for faster cash flow.